Search

Your search keyword '"Silvia Mengarelli"' showing total 7 results
Start Over Author "Silvia Mengarelli"
7 results on '"Silvia Mengarelli"'

1. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma

Author

Federico Piñero, Mario Tanno, Gabriel Aballay Soteras, Matías Tisi Baña, Melisa Dirchwolf, Eduardo Fassio, Andrés Ruf, Silvia Mengarelli, Silvia Borzi, Nora Fernández, Ezequiel Ridruejo, Valeria Descalzi, Margarita Anders, Guillermo Mazzolini, Virginia Reggiardo, Sebastián Marciano, Florencia Perazzo, Juan Carlos Spina, Lucas McCormack, Martín Maraschio, Cecilia Lagues, Adrián Gadano, Federico Villamil, Marcelo Silva, Fernando Cairo, and Beatriz Ameigeiras

Subjects
Liver cancer, Practice guideline, Latin America, Argentina, Specialties of internal medicine, RC581-951
Abstract

The A.A.E.E.H has developed this guideline for the best care of patients with hepatocellular carcinoma (HCC) from Argentina. It was done from May 2018 to March 2020. Specific clinical research questions were systematically searched. The quality of evidence and level of recommendations were organized according to GRADE. HCC surveillance is strongly recommended with abdominal ultrasound (US) every six months in the population at risk for HCC (cirrhosis, hepatitis B or hepatitis C); it is suggested to add alpha-feto protein (AFP) levels in case of inexeperienced sonographers. Imaging diagnosis in patients at risk for HCC has high specificity and tumor biopsy is not mandatory. The Barcelona Clinic Liver Cancer algorithm is strongly recommended for HCC staging and treatment-decision processes. Liver resection is strongly recommended for patients without portal hypertension and preserved liver function. Composite models are suggested for liver transplant selection criteria. Therapies for HCC with robust clinical evidence include transarterial chemoembolization (TACE) and first to second line systemic treatment options (sorafenib, lenvatinib, regorafenib, cabozantinib and ramucirumab). Immunotherapy with nivolumab and pembrolizumab has failed to show statistical benefit but the novel combination of atezolizumab plus bevacizumab has recently shown survival benefit over sorafenib in frontline.

Published
2020
Full Text
View/download PDF

2. Perfil epidemiológico molecular de la infección por el virus de la Hepatitis C en la región central de Argentina

Author

Viviana E. Ré, Adrián A. Farías, María P. Díaz, María B. Pisano, Silvia Mengarelli, Luis Kremer, Osvaldo Elbarcha, and Marta Contiagiani

Subjects
Virus de la hepatitis C (HCV), genotipos, epidemiología molecular, coinfección HCV/HIV, Argentina, Medicine (General), R5-920, Public aspects of medicine, RA1-1270
Abstract

La presencia de RNA-HCV y la distribución de genotipos se detectaron mediante técnicas moleculares (RT-nested PCR y RFLP) en 310 muestras de individuos de la región centro de Argentina. Se halló 11,8% de coinfección HCV/HIV, con mayor prevalencia de genotipo 1 (73%). La distribución de los genotipos 1 y 2 entre individuos monoinfectados fue de 49,4% y 43,9%, respectivamente. El análisis de regresión logística multivariado mostró que la edad y el uso de drogas endovenosas (UDEV) condicionó la distribución de genotipos. El genotipo 2 se halló frecuentemente entre adultos mayores y su diseminación no se pudo asociar a ninguna vía de transmisión. El genotipo 1 se lo halló principalmente en adultos jóvenes y asociados al UDEV. El notable incremento de genotipo 1, homogéneamente distribuido en todas las edades posee importantes implicancias en las decisiones terapéuticas, considerando que posee baja respuesta a la terapia antiviral.

Published
2014
Full Text
View/download PDF

3. Phylodynamics of hepatitis C virus subtype 2c in the province of Córdoba, Argentina.

Author

Viviana E Ré, Andrés C A Culasso, Silvia Mengarelli, Adrián A Farías, Fabián Fay, María B Pisano, Osvaldo Elbarcha, Marta S Contigiani, and Rodolfo H Campos

Subjects
Medicine, Science
Abstract

The Hepatitis C Virus Genotype 2 subtype 2c (HCV-2c) is detected as a low prevalence subtype in many countries, except in Southern Europe and Western Africa. The current epidemiology of HCV in Argentina, a low-prevalence country, shows the expected low prevalence for this subtype. However, this subtype is the most prevalent in the central province of Córdoba. Cruz del Eje (CdE), a small rural city of this province, shows a prevalence for HCV infections of 5%, being 90% of the samples classified as HCV-2c. In other locations of Córdoba Province (OLC) with lower prevalence for HCV, HCV-2c was recorded in about 50% of the samples. The phylogenetic analysis of samples from Córdoba Province consistently conformed a monophyletic group with HCV-2c sequences from all the countries where HCV-2c has been sequenced. The phylogeographic analysis showed an overall association between geographical traits and phylogeny, being these associations significant (α = 0.05) for Italy, France, Argentina (places other than Córdoba), Martinique, CdE and OLC. The coalescence analysis for samples from CdE, OLC and France yielded a Time for the Most Common Recent Ancestor of about 140 years, whereas its demographic reconstruction showed a "lag" phase in the viral population until 1880 and then an exponential growth until 1940. These results were also obtained when each geographical area was analyzed separately, suggesting that HCV-2c came into Córdoba province during the migration process, mainly from Europe, which is compatible with the history of Argentina of the early 20th century. This also suggests that the spread of HCV-2c occurred in Europe and South America almost simultaneously, possibly as a result of the advances in medicine technology of the first half of the 20th century.

Published
2011
Full Text
View/download PDF

4. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma

Author

Juan Carlos Spina, Mario Tanno, Cecilia Lagues, Ezequiel Ridruejo, Margarita Anders, Silvia Borzi, Matías Tisi Baña, Adrián Gadano, Andrés Ruf, Melisa Dirchwolf, Federico Piñero, Marcelo Silva, Guillermo Mazzolini, Nora Fernández, Eduardo Fassio, Martín Maraschio, Florencia Perazzo, Beatriz Ameigeiras, Lucas McCormack, Valeria Descalzi, Gabriel Aballay Soteras, Sebastián Marciano, Silvia Mengarelli, Virginia Reggiardo, Federico G. Villamil, and Fernando Cairo

Subjects
Oncology, Biopsy, Specialties of internal medicine, Medical Oncology, 0302 clinical medicine, Risk Factors, purl.org/becyt/ford/3.2 [https], LIVER CANCER, Ultrasonography, ARGENTINA, Evidence-Based Medicine, Liver Neoplasms, General Medicine, Hepatitis C, Treatment Outcome, RC581-951, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, purl.org/becyt/ford/3 [https], Liver cancer, Algorithms, medicine.drug, Sorafenib, medicine.medical_specialty, Practice guideline, Carcinoma, Hepatocellular, Consensus, Clinical Decision-Making, Argentina, Risk Assessment, LATIN AMERICA, Ramucirumab, Decision Support Techniques, 03 medical and health sciences, Atezolizumab, Predictive Value of Tests, Internal medicine, medicine, Humans, neoplasms, Neoplasm Staging, Hepatology, business.industry, Guideline, medicine.disease, digestive system diseases, Latin America, PRACTICE GUIDELINE, Liver function, business
Abstract

The A.A.E.E.H has developed this guideline for the best care of patients with hepatocellular carcinoma (HCC) from Argentina. It was done from May 2018 to March 2020. Specific clinical research questions were systematically searched. The quality of evidence and level of recommendations were organized according to GRADE. HCC surveillance is strongly recommended with abdominal ultrasound (US) every six months in the population at risk for HCC (cirrhosis, hepatitis B or hepatitis C); it is suggested to add alpha-feto protein (AFP) levels in case of inexeperienced sonographers. Imaging diagnosis in patients at risk for HCC has high specificity and tumor biopsy is not mandatory. The Barcelona Clinic Liver Cancer algorithm is strongly recommended for HCC staging and treatment-decision processes. Liver resection is strongly recommended for patients without portal hypertension and preserved liver function. Composite models are suggested for liver transplant selection criteria. Therapies for HCC with robust clinical evidence include transarterial chemoembolization (TACE) and first to second line systemic treatment options (sorafenib, lenvatinib, regorafenib, cabozantinib and ramucirumab). Immunotherapy with nivolumab and pembrolizumab has failed to show statistical benefit but the novel combination of atezolizumab plus bevacizumab has recently shown survival benefit over sorafenib in frontline. Fil: Piñero, Federico. Universidad Austral. Hospital Universitario Austral; Argentina Fil: Tanno, Mario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Hospital Nacional del Centenario; Argentina Fil: Aballay Soteras, Gabriel. Ministerio de Defensa. Ejército Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; Argentina Fil: Tisi Baña, Matías. Universidad Austral. Hospital Universitario Austral; Argentina Fil: Dirchwolf, Melisa. Hospital Privado de Rosario; Argentina Fil: Fassio, Eduardo. Hospital Nacional Profesor Alejandro Posadas.; Argentina Fil: Ruf, Andrés. Hospital Privado de Rosario; Argentina Fil: Mengarelli, Silvia Estela. Gobierno de la Provincia de Entre Rios. Hospital San Roque.; Argentina Fil: Borzi, Silvia. Hospital Privado de Cordoba; Argentina Fil: Fernández, Nora. Hospital Británico de Buenos Aires; Argentina Fil: Ridruejo, Ezequiel. Universidad Austral. Hospital Universitario Austral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina Fil: Descalzi, Valeria. Fundación Favaloro; Argentina Fil: Anders, Margarita. Hospital Alemán; Argentina Fil: Mazzolini, Guillermo. Universidad Austral; Argentina Fil: Reggiardo, Virginia. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Doctor Cosme Argerich; Argentina Fil: Marciano, Sebastian. Hospital Italiano. Departamento de Medicina.; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Perazzo, Florencia. Hospital Británico de Buenos Aires; Argentina Fil: Spina, Juan Carlos. Hospital Italiano; Argentina Fil: McCormack, Lucas. Hospital Alemán; Argentina Fil: Maraschio, Martín Alejandro. Hospital Privado de Cordoba; Argentina Fil: Lagues, Cecilia. Universidad Austral; Argentina Fil: Gadano, Adrián Carlos. Hospital Italiano. Departamento de Medicina.; Argentina Fil: Villamil, Federico. Hospital Italiano. Departamento de Medicina.; Argentina. Hospital Británico de Buenos Aires; Argentina Fil: Silva, Marcelo. Universidad Austral. Hospital Universitario Austral; Argentina Fil: Cairo, Fernando. Hospital Británico de Buenos Aires; Argentina Fil: Ameigeiras, Beatriz. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina

Published
2020

5. Incidence of de-novo hepatocellular carcinoma after treatment with direct antiviral agents for hepatitis C: A multicenter prospective cohort study from Latin America

Author

Daniela Perez, C. Gadea, Manuel Mendizabal, Alejandro Soza, Nelia Hernández, C. Mendoza, Raymundo Paraná Filho, Cristina Alonso, Federico Piñero, Fernando Barreyro, Ana Palazzo, Ezequiel Ridruejo, V. Moreno, Maria Isabel Schinoni, Adriana Varón, M. Silva, J. Vila, Susana Ceballos, Maria Virginia Reggiardo, Silvia Mengarelli, Andres Bruno, Marcela Sixto, and María Grazia Videla Zuain

Subjects
medicine.medical_specialty, Latin Americans, Hepatology, business.industry, Incidence (epidemiology), Hepatitis C, medicine.disease, Gastroenterology, Internal medicine, Hepatocellular carcinoma, medicine, Prospective cohort study, business, After treatment
Published
2018
Full Text
View/download PDF

6. Safety and effectiveness comparing generic and original sofosbuvir-based treatment regimens in patients with hepatitis C: A prospective multicenter study from Argentina

Author

Andres Bruno, Marcela Sixto, Manuel Mendizabal, María Grazia Videla Zuain, Cristina Alonso, Daniela Perez, Susana Ceballos, Silvia Mengarelli, Fernando Barreyro, C. Mendoza, Ana Palazzo, Ezequiel Ridruejo, M. Silva, J. Vila, V. Moreno, C. Gadea, N. Ratusnu, Federico Piñero, and Maria Virginia Reggiardo

Subjects
medicine.medical_specialty, Hepatology, Sofosbuvir, Treatment regimen, business.industry, Hepatitis C, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Multicenter study, Internal medicine, Medicine, 030211 gastroenterology & hepatology, In patient, 030212 general & internal medicine, business, medicine.drug
Published
2018
Full Text
View/download PDF

7. Detection of hepatitis C virus (HCV) in body fluids from HCV monoinfected and HCV/HIV coinfected patients

Author

Adrián, Farías, Viviana, Ré, Silvia, Mengarelli, Luis, Kremer, Maria Belén, Pisano, Luis, Allende, Juan, Nicolás, Osvaldo, Elbarcha, and Marta, Contigiani

Subjects
Adult, Male, Vaginal Smears, Chi-Square Distribution, Genotype, Reverse Transcriptase Polymerase Chain Reaction, HIV Infections, Cervix Uteri, Hepacivirus, Middle Aged, Hepatitis C, Body Fluids, Risk Factors, Semen, Leukocytes, Mononuclear, Humans, RNA, Viral, Female, Prospective Studies, Saliva
Abstract

The possibility of the non-parenteral Hepatitis C Virus (HCV) transmission is supported by the demonstration that the actual virus is present in several body fluids. In this study, we investigated the relationship between the detection of HCV RNA in body fluids (saliva, cervical smears, seminal fluid and peripheral blood mononuclear cells) from chronically HCV-infected patients and several viral and host factors.This study comprised 16 HIV/ HCV coinfected and 21 HCV monoinfected patients with a median age of 38 and 45 years, respectively. HCV-RNA was detected in serum and fluids samples by reverse transcription-nested polymerase chain reaction. Genotypes were determined by using RFLP and direct nucleotide sequencing of the PCR products and plasma viral loads by using NASBA HCV-QT.When compared on the basis of the results of the detection of HCV-RNA in fluids, patients did not differ significantly in relation to viral load, genotype, HCV/HIV coinfection, and epidemiological host factors.Our data suggest that HCV can be detected in body fluids of chronically HCV-infected patients independent of these cofactors, including circulating HCV load and HCV/HIV coinfection. Studies on HCV dynamics are needed to gain insights into nonparenteral transmission of HCV.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results